Because of the way the bullet point is phrased, I am assuming that 1,900 is the enrolled # for Phase 3.

But let's say I am wrong and the dosed is indeed 1,900 (and 1,900 is NOT enrolled).  Then deducting from the 798 from earlier trials, we get 1,100 or so as dosed patients.  If Phase 3 was indeed 50:50, then we were around 2,200 total enrolled as of March 2019.  

But if it is 2,200 enrolled, then patient years go up that much more.  More patient years is one of the 2 most favorable outcomes for RRR (the other being a higher MACE rate for placebo).  By my estimates, that adds at least 200 patient years to the total.